Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1157-1162

  Metzger, Ralf ^a,c   Vallbohmer, Daniel ^a   Müller Tidow, Carsten ^b   Higashi, Hiroshi ^a,d   Bollschweiler, Elfriede ^a   Warnecke Eberz, Ute ^a   Brabender, Jan ^a   Baldus, Stephan E ^c   Xi, Huan ^e   Berdel, Wolfgang E ^b   Serve, Hubert ^b   Hoelscher, Arnulf H ^a   Schneider, Paul M ^a,f  

^a Department of General Visceral and Cancer Surgery   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e BEIJING HOSPITAL   (China)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

hTEKT mRNA; Lung cancer; RT PCR; Survival; Telomerase; TRAP

Indexed keywords

MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; REAL TIME POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TELOMERASE;

EID: 64949176053     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Singh GK, Miller BA and Hankey BF: Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part II-Lung and colorectal cancers. J Natl Cancer Inst 94: 916-925, 2002.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN and Edwards BK: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: 1276-1299, 2003.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
4. Altshuler ML, Severin SE and Glukhov AI: The tumor cell and telomerase. Biochemistry (Mosc) 68: 1275-1283, 2003.
5. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB and Morin GB: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17: 498-502, 1997.
6. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352, 1998.
7. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA and Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3: 1271-1274, 1997.
8. Shay JW and Wright WE: Telomerase activity in human cancer. Curr Opin Oncol 8: 66-71, 1996.
9. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959, 1997.
10. De Kok JB, Schalken JA, Aalders TW, Ruers TJ, Willems HL and Swinkels DW: Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 87: 217-220, 2000.
11. Gertler R, Rosenberg R, Strieker D, Werner M, Lassmann S, Ulm K, Nekarda H and Siewert JR: Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer 95: 2103-2111, 2002.
12. Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer KL, Braun Y, Schuck A, Lanvers C, Bankfalvi A, Kneif S, Torhorst J, Zuber M, Kochli OR, Mross F, Dieterich H, Sauter G, Stein H, Fogt F and Boecker W: Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 198: 181-189, 2002.
13. Wang L, Soria JC, Kemp BL, Liu DD, Mao L and Khuri FR: hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 8: 2883-2889,2002.
14. Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L, Barassi F, Salvatore S, Chella A, Angeletti CA, Roncalli M, Coggi G and Bosari S: Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 82: 729-736, 2002.
15. Fujita Y, Fujikane T, Fujiuchi S, Nishigaki Y, Yamazaki Y, Nagase A, Shimizu T, Ohsaki Y and Kikuchi K: The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 98: 1008-1013, 2003.
16. Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, Brichon PY, Sabatier L, Brambilla C and Brambilla E: Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 90: 1222-1229, 2004.
17. Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA and Tsao MS: Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small cell lung cancer. Br J Cancer 94: 1452-1459,2006.
18. Arinaga M, Shimizu S, Gotoh K, Haruki N, Takahashi T and Mitsudomi T: Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Ann Thorac Surg 70: 401-405, 2000.
19. Kumaki F, Kawai T, Hiroi S, Shinomiya N, Ozeki Y, Ferrans VJ and Torikata C: Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 32: 188-195,2001.
20. Toomey D, Smyth G, Condron C, Kay E, Conroy R, Foley D, Hong C, Hogan B, Toner S, McCormick P, Broe P, Kelly C and Bouchier-Hayes D: Immune function, telomerase, and angiogenesis in patients with primary, operable non-small cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer 92: 2648-2657,2001
21. Wu TC, Lin P, Hsu CP, Huang YJ, Chen CY, Chung WC, Lee H and Ko JL: Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. Lung Cancer 41: 163-169, 2003.
22. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK and Khuri FR: Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22: 4575-4583,2004.
23. Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH and Roth JA: Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83: 473-479, 2000.
24. Sobin LH and Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80: 1803-1804, 1997.
25. Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001, 1996.
26. Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996.
27. Livak KJ, Flood SJ, Marmaro J, Giusti W and Deetz K: Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4: 357-362, 1995.
28. LeBlanc M and Crowley J: Relative risk trees for censored survival data. Biometrics 48: 411-425, 1992.
29. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
30. LeBlanc M, Jacobson J and Crowley J: Partitioning and peeling for constructing prognostic groups. Stat Methods Med Res 11: 247-274,2002.